1. Home
  2. SKY vs TGTX Comparison

SKY vs TGTX Comparison

Compare SKY & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SKY

Skyline Champion Corporation

HOLD

Current Price

$90.99

Market Cap

5.3B

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$31.02

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKY
TGTX
Founded
2010
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
5.0B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
SKY
TGTX
Price
$90.99
$31.02
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$101.00
$51.60
AVG Volume (30 Days)
599.0K
2.4M
Earning Date
02-03-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
48.48
N/A
EPS
3.84
2.78
Revenue
$2,624,539,000.00
$531,898,000.00
Revenue This Year
$7.67
$87.88
Revenue Next Year
$4.67
$47.78
P/E Ratio
$23.89
$11.24
Revenue Growth
12.14
100.88
52 Week Low
$59.44
$25.28
52 Week High
$110.00
$46.48

Technical Indicators

Market Signals
Indicator
SKY
TGTX
Relative Strength Index (RSI) 50.88 54.49
Support Level $92.36 $29.80
Resistance Level $97.30 $32.55
Average True Range (ATR) 3.29 1.63
MACD -0.41 0.30
Stochastic Oscillator 44.63 67.80

Price Performance

Historical Comparison
SKY
TGTX

About SKY Skyline Champion Corporation

Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business with 72 retail locations across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several dispatch locations across the United States.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: